With glyphosate-cancer settlement nearing, is the Roundup controversy coming to an end?

Credit: Daniel Acker/Bloomberg

Bayer AG is close to a turning point in its legal battle over the weedkiller Roundup. But it still has work to do to convince investors that buying Monsanto made sense.

The German drug and agriculture giant reached verbal agreements to resolve tens of thousands of U.S. cancer lawsuits over its Roundup weedkiller, Bloomberg News reported [May 25]. While the deals have yet to be signed, they cover an estimated 50,000 to 85,000 cases out of a total of some 125,000 lawsuits ….

Bayer still has to pay $191 million in the three Roundup trials it lost in the U.S., after judges slashed the initial combined damages of $2.4 billion awarded by juries. The fact that Bayer is trying to appeal those cases may be designed to send a signal on future claims that it won’t just roll over and pay, said Carl Tobias, a University of Richmond professor who specializes in mass-tort law.


Read the original post

Related article:  Adoption of GMO crops could improve health of Chinese farmers
Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend